Epizyme Inc
F:EPE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value of EPE.
The Intrinsic Value is calculated as the average of DCF and Relative values:
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
S
|
Seagen Inc
F:SGT
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Significant reliance on Tazemetostat exposes Epizyme to concentrated revenue risk, and any clinical or regulatory setbacks for this lead asset could materially reduce the firm’s prospects.
Tazemetostat’s successful initial approvals for advanced epithelioid sarcoma and certain follicular lymphoma settings could open the door to broader label expansions and make Epizyme an important player in epigenetic oncology.
Revenue & Expenses Breakdown
Epizyme Inc
Balance Sheet Decomposition
Epizyme Inc
| Current Assets | 186.8m |
| Cash & Short-Term Investments | 144.4m |
| Receivables | 11.2m |
| Other Current Assets | 31.2m |
| Non-Current Assets | 77.3m |
| PP&E | 19.2m |
| Intangibles | 40.8m |
| Other Non-Current Assets | 17.4m |
| Current Liabilities | 35m |
| Accounts Payable | 5m |
| Accrued Liabilities | 30m |
| Non-Current Liabilities | 249.5m |
| Long-Term Debt | 232.9m |
| Other Non-Current Liabilities | 16.6m |
Free Cash Flow Analysis
Epizyme Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Epizyme Inc
|
Revenue
|
53m
USD
|
|
Cost of Revenue
|
-13m
USD
|
|
Gross Profit
|
40.1m
USD
|
|
Operating Expenses
|
-236.2m
USD
|
|
Operating Income
|
-196.2m
USD
|
|
Other Expenses
|
-11.6m
USD
|
|
Net Income
|
-207.7m
USD
|
EPE Profitability Score
Profitability Due Diligence
Epizyme Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Epizyme Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
EPE Solvency Score
Solvency Due Diligence
Epizyme Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Epizyme Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPE Price Targets Summary
Epizyme Inc
Dividends
Current shareholder yield for EPE is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?